RxDoctor Payments Data

Frank Houston, PA

Physician Assistant · Asheboro, NCNPI 1598277691

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.9%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.2% of it on its own, with 26 other manufacturers making up the rest. Among physician assistant clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,637in general payments, 2019–2025

Across 830 payments — averaging $35.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • Sanofi$2K
  • LEO Pharma Inc.$1K
  • Johnson & Johnson$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$947
  • plus $6K from 21 others

What the payments were for

  • Speaking & faculty fees$15,10051%
  • Food & beverage$14,01347%
  • Education$5252%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,637 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$88,640
Medicare patients
276
Services billed
1,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyriziRisankizumab-Rzaa33$689,592
Dupixent SyringeDupilumab54$206,568
OdomzoSonidegib Phosphate14$191,182
Dupixent PenDupilumab14$52,749
Clobetasol Propionate143$6,011
Doxycycline Hyclate199$3,569
Triamcinolone Acetonide230$2,144
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc24$1,429
Ketoconazole94$1,096
Tretinoin11$840
Fluocinonide14$756
Ciclopirox18$670
Mupirocin83$670
Minocycline Hcl41$574
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip25$559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$18,141$689,59233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Asheboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →